OPM and Biomet
The deal will give Biomet exclusive distribution rights to OPM's OsteoFab Patient Specific Cranial Device (OPSCD) and OsteoFab implants for craniomaxillofacial (CMF).
President and Chief Executive Officer of OPM Scott DeFelice stated: "Following the universally positive response from our initial clients, it is with great satisfaction that we announce this global strategic cooperation with Biomet.
"We concluded that Biomet was the best partner based upon their existing product mix, global market presence, exceptional focus on Patient-Specific solutions, and clear reputation as a technological leader within the cranial and orthopedic industries."
OPM and Biomet performed the first clinical application in the United States earlier this year.
OPM's OsteoFab technology combines OXPEKK-IG polymer (PEKK or polyetherketoneketone) - a biocompatible material with properties like bone - with a unique additive manufacturing process to 3D print products ranging from bespoke devices to patient-specific designs created directly from a CT or MRI scan.
OXPEKK-IG polymer has been used in implant devices for seven years and is supported by extensive biocompatibility and clinical data. OPM has recently completed a multimillion-dollar capital project resulting in a state-of-the-art biomedical additive manufacturing facility located in South Windsor, Connecticut.
Mr DeFelice noted: "We have steadfastly held to our vision that if we could additively produce an implant designed directly from a patient's MRI or CT in a biocompatible structural polymer, we would advance human health and well-being while respecting healthcare market realities."
OPM began producing CMF implants as a contract manufacturer in late 2011 and received FDA clearance for their own OPSCD in February 2013.